Latest Articles
-
What Does Recent Biosimilar Approval By The FDA Mean?
In early March, Novartis’ Zarxio became the first biosimilar to be approved in the U.S. by the FDA. A couple of weeks later, Amgen in Federal court was denied in its bid for a preliminary injunction to delay the sale of Zarxio in an attempt...
-
These Two Catalysts Can Move Merck’s Stock Up
Despite the recent pressure on revenues resulting from loss of patent exclusivity for some drugs and adverse currency movements, Merck (NYSE:MRK) continues t0 streamline its research and development expenses and execute in key growth markets. Th...
-
Merck’s Partnership With NGM Is A Bold Move
Last week Merck (NYSE:MRK) signed a deal with NGM Biopharmaceuticals, which we believe is a bold and a long-term move. Under the multi-year agreement, Merck will make a payment of $95 million to NGM to establish a co-development alliance and ac...
-
Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakthrough Designation
Merck (NYSE:MRK) posted disappointing numbers in its Q4 2014 and full year results recently. While its diabetes and immunology drugs continued to perform well, weakness in the cardiovascular segment, a decline in vaccine revenues and the continue...
-
Merck Earnings Preview
Merck (NYSE:MRK) will release its Q4 2014 earnings on February 4th. The company will continue its battle against the revenue decline which has intensified in recent years due to strong competition from generics. Even though its diabetes and immun...
-
The Year 2014 In Review: Everyone Is Looking At Merck’s R&D Pipeline
The year 2014 wasn’t exactly spectacular for Merck (NYSE:MRK). The company continued to battle a revenue decline resulting from the patent expiry of key drugs. Even though its diabetes and immunology franchises have been offseting this dec...
-
Quick Analysis Of Merck’s Acquisition Of Cubist
Merck (NYSE:MRK) has announced that it will acquire Cubist Pharmaceuticals for $8.4 billion. This year has been busy with M&A (mergers and acquisitions) activity in the pharmaceutical industry and Merck has been especially focused on mid-siz...
-
Rolling with Biotech’s Regulatory Punches: Chen Lin
Submitted by The Life Sciences Report as part of our contributors program . Rolling with Biotech’s Regulatory Punches: Chen Lin This interview was conducted by Peter Byrne of The Life Sciences Report . Being temporarily burned by the U...
-
Merck Enters Ebola Vaccine Race
Merck (NYSE:MRK) is the latest among the big pharmaceutical firms to join Ebola Vaccine race. The company has just announced a deal with NewLink Genetics under which Merck will get the rights to the latter’s experimental vaccine for Ebola v...
-
Do Merck’s Recent Hepatits C Trial Results Weaken Its Position?
Merck (NYSE:MRK) recently released some data from clinical trials of a triple-pill regimen for the treatment of treatment-naive group of cirrhotic patients. Cirrhotic patients refer to individuals with significant liver scarring, or the replaceme...
-
Merck Falls On Slightly Weak Results
Merck ‘s (NYSE:MRK) shares slid slightly as the company reported another quarter plagued by revenue decline. While its diabetes and immunology drugs continued to be the face savers, weakness in the Hepatitis C franchise, a decline in vaccin...
-
Merck Earnings Preview: Expect Continued Pressure On Topline Growth
Merck (NYSE:MRK) will release its Q3 2014 earnings on October 27th. While we expect a continued decline in legacy products, revenues from its diabetes, drugs as well as anti-infective medicines and Remicade, will continue to grow. The story for M...
-
Weekly Pharma Notes: Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Merck And Roche
Last week was not very eventful for big pharmaceutical companies, except for few announcements here and there. However, pharmaceutical stocks declined slightly due to broader market fall. For investors, it will be worthwhile to look forward to co...
-
How Significant Can Keytruda Be For Merck?
Merck (NYSE:MRK) recently received FDA approval for its new immuno-oncology drug Keytruda (pembrolizumab). The company beat Bristol-Myers Squibb in terms of getting the drug market ready, but the latter sued it for patent infringement. The drug w...
-
Weekly Pharma Notes: Bristol-Myers Squibb, Johnson & Johnson, Merck And Roche
Last week saw some new drug approvals in the pharmaceutical sector. While Merck launched its new anti-PD 1 therapy, Roche got European Union approval for expanded use of its rheumatoid Arthritis drug. Merck’s shares inched higher on the new...
